Top news of the week: 05.07.2022.
ARCH Venture Partners raises $3 billion fund to invest in biotech startups despite brutal stock downturn
The market for biotechnology stocks is ghastly, but ARCH Venture Partners, one of the largest and most prolific investors in early stage biotech startups, is doubling down.
An Open Letter from Female Biotech Leaders on Post-Roe America
[Editor’s Note: this letter was drafted by female biotech leaders in response to the Supreme Court’s Dobbs decision. It was co-signed by more than 65 female biotech executives as of July 1. ...
Arch brings in another $3B for biotech startup investing
The venture firm’s largest-ever haul comes about a year and a half after it raised another $2 billion and amidst an historic downturn for the sector.
Crunching the numbers on the first half drought for biotech IPOs
Data compiled by BioPharma Dive show a growing gap in the frequency and size of new offerings compared to prior years. Some analysts believe as many as a third of public biotechs must “go ...
Bayer, Amgen back ReCode’s plan to broaden genetic medicine’s reach
The two drugmakers joined a long list of investors, including Pfizer and Sanofi, that have been funding the startup’s plan to develop a new type of lipid nanoparticle technology.
June 29, 2022
Artizan Biosciences: Signs Lease at Winchester Works in New Haven More CNS Pharmaceuticals: Receives Approval From U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal …
Accelerating health and startups
Merck's Digital Sciences Studio is a startup accelerator in the digital health space. Investing, supporting, and mentoring startups using Merck's network.
Heron, Avadel Slash Headcount, Brace for Economic Downturn
Heron Therapeutics and Avadel Pharmaceuticals have now joined the ranks of life sciences companies cutting costs including laying off a significant number of employees.